Shopping Cart 0
Cart Subtotal
USD 0

Malignant Mesothelioma - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Malignant Mesothelioma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 35, 33, 17, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 5 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma-Overview 6

Malignant Mesothelioma-Therapeutics Development 7

Malignant Mesothelioma-Therapeutics Assessment 22

Malignant Mesothelioma-Companies Involved in Therapeutics Development 36

Malignant Mesothelioma-Drug Profiles 68

Malignant Mesothelioma-Dormant Projects 733

Malignant Mesothelioma-Discontinued Products 736

Malignant Mesothelioma-Product Development Milestones 737

Appendix 751


List Of Figure

List of Figures

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Malignant Mesothelioma-Pipeline by Advantagene Inc, H2 2018

Malignant Mesothelioma-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Almac Discovery Ltd, H2 2018

Malignant Mesothelioma-Pipeline by AnGes Inc, H2 2018

Malignant Mesothelioma-Pipeline by Argenx SE, H2 2018

Malignant Mesothelioma-Pipeline by ArQule Inc, H2 2018

Malignant Mesothelioma-Pipeline by AstraZeneca Plc, H2 2018

Malignant Mesothelioma-Pipeline by Bayer AG, H2 2018

Malignant Mesothelioma-Pipeline by BerGenBio ASA, H2 2018

Malignant Mesothelioma-Pipeline by Biocad, H2 2018

Malignant Mesothelioma-Pipeline by Biogen Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bionomics Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Biotecnol Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Boston Biomedical Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Malignant Mesothelioma-Pipeline by Calithera Biosciences Inc, H2 2018

Malignant Mesothelioma-Pipeline by CanBas Co Ltd, H2 2018

Malignant Mesothelioma-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Checkpoint Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Clovis Oncology Inc, H2 2018

Malignant Mesothelioma-Pipeline by Concordia International Corp, H2 2018

Malignant Mesothelioma-Pipeline by Eli Lilly and Co, H2 2018

Malignant Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Epizyme Inc, H2 2018

Malignant Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Genelux Corp, H2 2018

Malignant Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2018

Malignant Mesothelioma-Pipeline by Horizon Pharma Plc, H2 2018

Malignant Mesothelioma-Pipeline by Incyte Corp, H2 2018

Malignant Mesothelioma-Pipeline by Infinity Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Inventiva, H2 2018

Malignant Mesothelioma-Pipeline by Juno Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Karyopharm Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Laboratoires Pierre Fabre SA, H2 2018

Malignant Mesothelioma-Pipeline by MacroGenics Inc, H2 2018

Malignant Mesothelioma-Pipeline by MedImmune LLC, H2 2018

Malignant Mesothelioma-Pipeline by MELEMA Pharma GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Merck & Co Inc, H2 2018

Malignant Mesothelioma-Pipeline by Merck KGaA, H2 2018

Malignant Mesothelioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Malignant Mesothelioma-Pipeline by MolMed SpA, H2 2018

Malignant Mesothelioma-Pipeline by Morphotek Inc, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment


Companies

Advantagene Inc

Aldeyra Therapeutics Inc

Almac Discovery Ltd

AnGes Inc

Argenx SE

ArQule Inc

AstraZeneca Plc

Bayer AG

BerGenBio ASA

Biocad

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Concordia International Corp

Eli Lilly and Co

EnGeneIC Ltd

Epizyme Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Incyte Corp

Infinity Pharmaceuticals Inc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Laboratoires Pierre Fabre SA

MacroGenics Inc

MedImmune LLC

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

Novartis AG

Oasmia Pharmaceutical AB

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sorrento Therapeutics Inc

Targovax ASA

TCR2 Therapeutics Inc

TESARO Inc

TRACON Pharmaceuticals Inc

TREAT U SA

VasGene Therapeutics Inc

Venus Remedies Ltd

Verastem Inc

Vyriad Inc

Y's Therapeutics Co Ltd

Malignant Mesothelioma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 35, 33, 17, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 5 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma-Overview 6

Malignant Mesothelioma-Therapeutics Development 7

Malignant Mesothelioma-Therapeutics Assessment 22

Malignant Mesothelioma-Companies Involved in Therapeutics Development 36

Malignant Mesothelioma-Drug Profiles 68

Malignant Mesothelioma-Dormant Projects 733

Malignant Mesothelioma-Discontinued Products 736

Malignant Mesothelioma-Product Development Milestones 737

Appendix 751


List Of Figure

List of Figures

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Malignant Mesothelioma-Pipeline by Advantagene Inc, H2 2018

Malignant Mesothelioma-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Almac Discovery Ltd, H2 2018

Malignant Mesothelioma-Pipeline by AnGes Inc, H2 2018

Malignant Mesothelioma-Pipeline by Argenx SE, H2 2018

Malignant Mesothelioma-Pipeline by ArQule Inc, H2 2018

Malignant Mesothelioma-Pipeline by AstraZeneca Plc, H2 2018

Malignant Mesothelioma-Pipeline by Bayer AG, H2 2018

Malignant Mesothelioma-Pipeline by BerGenBio ASA, H2 2018

Malignant Mesothelioma-Pipeline by Biocad, H2 2018

Malignant Mesothelioma-Pipeline by Biogen Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bionomics Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Biotecnol Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Boston Biomedical Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Malignant Mesothelioma-Pipeline by Calithera Biosciences Inc, H2 2018

Malignant Mesothelioma-Pipeline by CanBas Co Ltd, H2 2018

Malignant Mesothelioma-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Checkpoint Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Clovis Oncology Inc, H2 2018

Malignant Mesothelioma-Pipeline by Concordia International Corp, H2 2018

Malignant Mesothelioma-Pipeline by Eli Lilly and Co, H2 2018

Malignant Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Epizyme Inc, H2 2018

Malignant Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Genelux Corp, H2 2018

Malignant Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2018

Malignant Mesothelioma-Pipeline by Horizon Pharma Plc, H2 2018

Malignant Mesothelioma-Pipeline by Incyte Corp, H2 2018

Malignant Mesothelioma-Pipeline by Infinity Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Inventiva, H2 2018

Malignant Mesothelioma-Pipeline by Juno Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Karyopharm Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Laboratoires Pierre Fabre SA, H2 2018

Malignant Mesothelioma-Pipeline by MacroGenics Inc, H2 2018

Malignant Mesothelioma-Pipeline by MedImmune LLC, H2 2018

Malignant Mesothelioma-Pipeline by MELEMA Pharma GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Merck & Co Inc, H2 2018

Malignant Mesothelioma-Pipeline by Merck KGaA, H2 2018

Malignant Mesothelioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Malignant Mesothelioma-Pipeline by MolMed SpA, H2 2018

Malignant Mesothelioma-Pipeline by Morphotek Inc, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment


Companies

Advantagene Inc

Aldeyra Therapeutics Inc

Almac Discovery Ltd

AnGes Inc

Argenx SE

ArQule Inc

AstraZeneca Plc

Bayer AG

BerGenBio ASA

Biocad

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Concordia International Corp

Eli Lilly and Co

EnGeneIC Ltd

Epizyme Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Incyte Corp

Infinity Pharmaceuticals Inc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Laboratoires Pierre Fabre SA

MacroGenics Inc

MedImmune LLC

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

Novartis AG

Oasmia Pharmaceutical AB

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sorrento Therapeutics Inc

Targovax ASA

TCR2 Therapeutics Inc

TESARO Inc

TRACON Pharmaceuticals Inc

TREAT U SA

VasGene Therapeutics Inc

Venus Remedies Ltd

Verastem Inc

Vyriad Inc

Y's Therapeutics Co Ltd